Loading...
Bilateral Trade Intelligence · $1.8K Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $1.8K worth of pharmaceutical formulations from Belarus across 2 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are GMC LLC ($1.8K). The leading products are Paracetamol ($2K). Average shipment value: $900.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Paracetamol | $1.8K | 100.0% |
India imports 1+ pharmaceutical formulations from Belarus with a combined trade value of $1.8K. Key products include Paracetamol ($2K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 2 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Belarus, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Belarus buyers, regulatory requirements, and logistics for that specific product corridor. Products include Paracetamol ($2K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Belarus. Leading exporters include Gmc Llc, . The top exporter accounts for 100.0% of total India–Belarus pharma exports. Source: Indian Customs (DGFT).
1 companies in Belarus import pharmaceutical formulations from India. Top buyers include Sun Pharmaceutical Industries Limited, . The largest buyer accounts for 100.0% of India–Belarus pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Belarus and India has remained relatively modest over the past five years. Between 2022 and 2026, India imported a total of $2,000 USD worth of pharmaceutical products from Belarus, comprising two shipments. This limited trade volume indicates a nascent and underdeveloped trade relationship in the pharmaceutical sector. The sole product imported during this period was paracetamol, highlighting a narrow product focus. The primary Belarusian supplier was GMC LLC, which accounted for both shipments, while the sole Indian buyer was Sun Pharmaceutical Industries Limited. The average shipment value stood at $900 USD, suggesting that the trade is in its infancy and may be constrained by factors such as regulatory complexities, logistical challenges, and limited market awareness.
Belarus's contribution to India's pharmaceutical imports is negligible, with a total import value of $2,000 USD over the past five years. This figure represents a minuscule fraction of India's overall pharmaceutical import market, which is predominantly supplied by countries like the United States, European Union members, and China. The limited trade volume from Belarus underscores the need for strategic initiatives to enhance bilateral trade relations, including addressing regulatory hurdles, improving logistical frameworks, and fostering business partnerships to diversify the product range and increase trade volume.
Between 2024 and 2026, there have been no significant policy changes by the Central Drugs Standard Control Organisation (CDSCO) specifically targeting pharmaceutical imports from Belarus. Similarly, no new trade agreements or regulatory harmonization efforts have been implemented to facilitate this trade corridor. The lack of such developments suggests a need for proactive engagement from both Belarusian and Indian stakeholders to identify and address barriers to trade, such as regulatory complexities, market access issues, and logistical challenges, to stimulate growth in this sector.
Registration process, GMP requirements, import documentation
For Belarusian pharmaceutical companies aiming to export products to India, obtaining registration with the Central Drugs Standard Control Organisation (CDSCO) is mandatory. The process involves several key steps:
1. Online Registration: Applicants must register on the CDSCO's SUGAM portal, providing details such as applicant type, organization name, and contact information.
2. Document Submission: Essential documents include a valid address proof of the firm (e.g., Certificate of Incorporation, GST Certificate), an undertaking form, and a valid ID proof of the authorized person.
3. Verification and Approval: After submission, the application undergoes verification by CDSCO Headquarters. Upon successful verification, the registration is approved, allowing the company to import pharmaceutical products into India.
The entire process is conducted online, aiming to streamline and expedite the registration procedure. However, the timeline for approval can vary, and applicants are advised to ensure all documentation is accurate and complete to avoid delays.
India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards to ensure the safety, efficacy, and quality of pharmaceutical products. For Belarusian manufacturers, this entails:
Adhering to these standards is crucial for Belarusian companies to establish credibility and ensure the acceptance of their products in the Indian market.
To import pharmaceutical products into India, Belarusian companies must prepare and submit the following documentation:
Ensuring all documentation is accurate and complete is essential to avoid delays or rejections during the import process.
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Belarus to India are currently limited to paracetamol, a widely used analgesic and antipyretic. This indicates a focus on generic, over-the-counter medications. The absence of imports in other therapeutic areas suggests potential opportunities for diversification into other product categories, such as antibiotics, cardiovascular drugs, or specialty medicines, to meet the diverse needs of the Indian market.
Given the current limited trade volume, there is minimal importation of innovator drugs, novel formulations, or advanced therapies from Belarus to India. Expanding the product range to include such specialty products could enhance the value proposition of Belarusian pharmaceutical exports and cater to unmet medical needs in India.
The primary driver for importing paracetamol from Belarus is likely cost-effectiveness, as generic formulations from Belarus may offer competitive pricing. Additionally, the need to diversify sources and reduce dependency on traditional suppliers could motivate Indian companies to explore imports from Belarus. However, factors such as regulatory compliance, quality assurance, and logistical considerations also play significant roles in the decision-making process.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
These duties and taxes are subject to periodic revisions. Importers should consult the latest notifications from the Directorate General of Foreign Trade (DGFT) and the Ministry of Finance for current rates.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Belarus concerning pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations. However, the absence of bilateral trade agreements may result in standard tariff rates being applied to imports. Engaging in discussions to establish such agreements could be beneficial for enhancing trade relations.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. This provision can impact the importation of certain pharmaceutical products. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. Imported pharmaceutical products are subject to price controls, which can affect their market competitiveness.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Belarus to India typically involve sea freight, given the distance and cost considerations. The journey from Belarus to major Indian ports such as Mumbai or Kolkata can take approximately 30 to 40 days, depending on the specific ports of departure and arrival, as well as the shipping route chosen. Air freight is less common due to higher costs but may be utilized for urgent shipments. Reliability of these routes is generally high, but factors such as geopolitical events, weather conditions, and port congestion can impact transit times.
Belarus does not have direct access to the sea; therefore, pharmaceutical exports are typically routed through neighboring countries with seaports, such as Lithuania or Latvia. In India, major ports handling pharmaceutical imports include Mumbai, Chennai, Kolkata, and Delhi. These ports are equipped with facilities to handle pharmaceutical products, including temperature-controlled storage for products requiring cold chain logistics.
Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of documentation, inspection of goods, and payment of applicable duties and taxes. The Central Drugs Standard Control Organisation (CDSCO) may conduct quality checks to ensure compliance with Indian standards. For products requiring cold chain logistics, adherence to Good Distribution Practice (GDP) is mandatory to maintain product integrity. Importers must ensure that their logistics
India exported pharmaceuticals worth $1.8K to Belarus across 2 verified shipments.
1. GMC LLC — $1.8K. Total: 1 suppliers.
1. SUN PHARMACEUTICAL INDUSTRIES LIMITED — $1.8K. 1 buyers total.
1. Paracetamol ($1.8K, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $1.8K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$900 per consignment across 2 shipments.
1 Indian companies. Largest: GMC LLC with $1.8K.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 2 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists